Vaccinations might be necessary every year, he said. Bourla made the comments April 1, but they were aired Thursday.
“We need to see what would be the sequence, and for how often we need to do that, that remains to be seen,” he said. “A likely scenario is that there will be … a need for a third dose, somewhere between six and 12 months. And from there, there will be an annual revaccination, but all of that needs to be confirmed. And again, the variants will play a key role.”
Thursday’s news didn’t affect Pfizer stock, which rose 1.2% in an up market Thursday to $37.61.
In other vaccine news, Gourla said Tuesday that Pfizer has ramped up production of its vaccine and can deliver 10% more doses to the U.S. than previously agreed by the end of May.
He wrote in a tweet that the company now anticipates delivering 220 million doses of the vaccine it developed jointly with BioNTech (BNTX) - Get Report by the end of next month, and all 300 million doses agreed on two weeks early, in July.
Meanwhile, the White House said Tuesday that the decision to pause the use of Johnson & Johnson’s vaccine won’t affect the national rollout of vaccines.